Page 51 - Recursion Pharmaceuticals News Today

Utah Business On April 20, 2021, Recursion Pharmaceuticals, Inc. of Salt Lake City announced the closing of its initial public offering of 27,878,787 shares of its Class A common stock at a price to the public at $18.00 per share, a price at the top end of its expected pricing range. Recursion shares began trading on the Nasdaq Global Select Market on Friday, April 16, 2021 under the symbol “RXRX.” That day the share price surged, rising as much as 82 percent. In the past week Recursion sha...

55 Biggest Movers From Yesterday Benzinga 2 hrs ago Gainers Marlin Business Services Corp. (NASDAQ: MRLN) shares surged 50.7% to close at $21.46 on Monday after the company enters into a definitive agreement to be acquired by funds managed by HPS Investment Partners for $23.50 per share in cash. Knoll, Inc. (NYSE: KNL) rose 35.2% to settle at $23.30 after the company announced it would be acquired by Herman Miller for $11 in cash and 0.32 shares of the combined company per Knoll share owned...

Recursion Pharmaceuticals Announces Pricing of Initial Public Offering News provided by Share this article Share this article SALT LAKE CITY, April 16, 2021 /PRNewswire/ -- Recursion Pharmaceuticals, Inc. ("Recursion" or "we") today announced the pricing of its initial public offering of its Class A common stock at a price to the public of $18.00 per share. Recursion is offering 24,242,424 shares of its Class A common stock. The gross proceeds from the offering, before deducting underwriting di...

Recursion Pharmaceuticals has set terms for a major $306 million IPO as the artificial intelligence biotech eyes a $3 billion valuation.

SALT LAKE CITY — Over the next 15 years, up to 300 new high-paying jobs could be coming to the state as four companies have partnered with the Utah Governors Office of Economic Development in a tax credit agreement. To qualify for the tax credit, eligible companies agree to meet certain parameters from the state, like bringing in new jobs and development, and in return they get their tax refund of up to 30%. If the business doesnt meet the requirements, the tax credit is off the table. Heres ...

Share this article SALT LAKE CITY, March 1, 2021 /PRNewswire/ -- Recursion, a digital biology company industrializing drug discovery, today announced the appointment of R. Martin Chavez as Chairman of its Board of Directors. Dr. Chavez, who joined Recursions Board of Directors in 2020, will serve as the companys first independent Chairman. In this role, Dr. Chavez will oversee the organizations goals with regard to investor relations and apply his career-long innovation expertise to support Re...

The changing dynamics of the Argininosuccinic aciduria market, Complement 3 glomerulopathy market, Dup15q syndrome market, Fragile X syndrome market, and Neurofibromatosis Type-2 (NF2) market: Analysis by DelveInsight Complement 3 glomerulopathy market landscape Dup15q syndrome Market Dup15q syndrome is a neurogenetic disorder that results from duplications of chromosome 15q11.2-13.1. It is characterized by hypotonia, developmental delay and intellectual disability (ID), epilepsy, and autism sp...

tanmayFebruary 8, 2021 11 The global Neurofibromatoses Type II Therapecutics Market report includes an overview, which interprets value chain structure, industrial environment, regional analysis, applications, types market size, and forecast. The report is integrated with imperative insights on the market which will support the clients to make precise business decisions. The report incorporates data regarding the supply and demand situation, the competitive scenario, and the challenges for ma...

AI Drug Development Investments Accelerated in 2020 News provided by Share this article Share this article MILTON KEYNES, England, Dec. 30, 2020 /PRNewswire/ -- The market for AI in Drug Development had a record year in 2020 with $2.9B new funding and a total funding in the industry reaching $9.2B. But while the annual investment value is reaching new heights, the number of funding rounds has continued its downfall. Emersion Insights has analysed the investment landscape and categorised the in...

[December 28, 2020] iBio Appoints Dr. Martin B. Brenner as Chief Scientific Officer BRYAN, Texas, Dec. 28, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced the appointment of Martin B. Brenner, DVM, Ph.D., as its Chief Scientific Officer (“CSO”), effective January 18, 2020. “We are thrilled to have Dr. Brenner join our team,” said Tom Isett, C...